GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » YoY EBITDA Growth

Genovis AB (FRA:5GV) YoY EBITDA Growth : 100.00% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genovis AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Genovis AB's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 100.00%.

Genovis AB's EBITDA per Share for the three months ended in Dec. 2024 was €0.01.

Genovis AB YoY EBITDA Growth Historical Data

The historical data trend for Genovis AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB YoY EBITDA Growth Chart

Genovis AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.86 258.33 -51.16 333.33 -10.99

Genovis AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 162.50 -59.02 -30.00 230.00 100.00

Genovis AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Genovis AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(0.081-0.091)/ | 0.091 |
=-10.99 %

Genovis AB's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(0.01-0.005)/ | 0.005 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Genovis AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovis AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » YoY EBITDA Growth
Comparable Companies
OSTO:EGTX OSTO:VICO OSTO:XSPRAY OSTO:HNSA OSTO:BINV OSTO:SANION OSTO:SYNACT OSTO:DMYD B XSAT:HAMLET B OSTO:IBT B VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
GENO:Sweden
Address
Scheelevagen 2, Box 790, Lund, SWE, SE-220 07
Website
https://www.genovis.com
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines